http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110343113-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2019-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110343113-B |
| titleOfInvention | Preparation method of tofacitinib intermediate |
| abstract | The invention provides a preparation method of a tofacitinib intermediate, and belongs to the technical field of biochemistry. The preparation method of the tofacitinib intermediate provided by the invention comprises the following steps: and (3) carrying out debenzylation reaction on the compound A, sodium formate, palladium carbon and a solvent to obtain the tofacitinib intermediate. The preparation method provided by the invention adopts sodium formate as a hydrogen donor to debenzylate to prepare the tofacitinib citrate intermediate, and compared with a preparation method adopting hydrogen as a hydrogen donor, the preparation method provided by the invention does not need pressurization and has safe reaction conditions; compared with hydrazine hydrate as a hydrogen donor, the method has no risk of flammability and explosiveness; compared to ammonium formate as hydrogen donor, there is no risk of the reactor being blocked by volatilization of the hydrogen donor. The preparation method provided by the invention has the advantages of safe reaction conditions, high yield and high purity, and is suitable for industrial production. |
| priorityDate | 2019-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.